<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35051">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01781520</url>
  </required_header>
  <id_info>
    <org_study_id>S1+DC CIK-P</org_study_id>
    <nct_id>NCT01781520</nct_id>
  </id_info>
  <brief_title>Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to  evaluate the antitumor effect and safety of clinical
      effectiveness S-1 plus dendritic cell activated Cytokine induced killer treatment (DC-CIK)
      for unresectable locally advanced pancreatic cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression free survival（PFS）</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Two year survival rate</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>4 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>S-1 plus DC-CIK</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chemotherapy: S-1 is administered orally twice daily at a dose of 80,100, or 120mg/day for body surface areas of less than 1.25m2, between 1.25m2 and less than 1.5, or 1.5m2 or greater, respectively, for 14 consecutive days, followed by a 7-day rest, repeated every 3 weeks.
DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition aphaeresis 3 days before administrating S-1 , and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>S-1 plus DC-CIK</intervention_name>
    <arm_group_label>S-1 plus DC-CIK</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed locally advanced, unresectable or
             metastatic adenocarcinoma of the pancreas not amenable to curative radiotherapy or
             surgery.

          -  Capable of oral intake

          -  Between 18 and 80 years old

          -  Measurable disease as defined by Response Evaluation Criteria in Solid Tumors
             (RECIST) criteria

          -  Karnofsky Performance Status (KPS) ≥ 70%

          -  Normal functions of heart, lung and bone marrow

          -  Adequate hematological profile： Hemoglobin ≥ 9.0 g/dL Absolute granulocyte count ≥
             1,500/mm3 Platelet count ≥ 100,000/mm3

          -  Adequate hepatic function Total bilirubin level≤ 3.0 times the upper limit of normal
             (ULN) Transaminases AST (SGOT) and ALT (SGPT) ≤ 2.5 times ULN

          -  Adequate renal function(normal serum creatinine level)

          -  A life expectancy≥ 2 months

          -  Informed consent signed

        Exclusion Criteria:

          -  Current enrollment in another clinical study with an investigational agent. Patients
             participating in surveys or observational studies are eligible to participate in this
             study

          -  Any radiotherapy or surgery within the previous 3 weeks

          -  Symptomatic brain metastasis not controlled by corticosteroids

          -  Bone marrow metastasis

          -  Active infection

          -  Serious complications

          -  Receiving a concomitant treatment with drugs interacting with S-1. The following
             drugs are prohibited because there may be an interaction with S-1: phenytoin,
             potassium warfarin , flucytosine, cimetidine and folinic acid.

          -  Pregnant or lactation women, or women with known or suspected pregnancy and men who
             want let to pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jun Ren, MD, PhD</last_name>
    <phone>86-10-63926317</phone>
    <email>renjun9688@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Capital Medical University Cancer Center</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Ren, MD, PhD</last_name>
      <phone>86-10-63926317</phone>
      <email>renjun9688@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Jun Ren, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>February 1, 2013</lastchanged_date>
  <firstreceived_date>January 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Jun Ren MD, PhD</investigator_full_name>
    <investigator_title>Director,Capital Medical University (CMU)Cancer Center</investigator_title>
  </responsible_party>
  <keyword>Pancreatic Cancer</keyword>
  <keyword>S1</keyword>
  <keyword>DC-CIK</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
